Core Viewpoint - Sanofi has decided to cease the promotion of its cholesterol-lowering drug, Polatad (Alirocumab injection), in the Chinese market due to global supply issues and a shift in its cardiovascular market strategy [1][6]. Market Dynamics - The PCSK9 market is becoming increasingly competitive, with more domestic alternatives being included in the National Medical Insurance Drug List, leading to a more diversified market [6][7]. - Polatad's market share has been significantly eroded by competitors, with sales figures showing a rise in sales for rival products like Repatha (from 130 million yuan to 1.323 billion yuan) while Polatad's sales increased from 17 million yuan to 629 million yuan during the same period [7]. Patient Impact - Patients using Polatad have expressed minimal concern regarding its withdrawal, indicating that they can easily switch to alternative medications without significant issues [2][5]. - Clinical experts have noted that the mechanism of action for PCSK9 inhibitors is similar across different products, suggesting that patients can transition between these medications without adverse effects [4][8]. Clinical Alternatives - Multiple alternatives to Polatad are available, including Repatha and domestic products like Xinbile (Torlipressin) and other PCSK9 monoclonal antibodies, which have been approved and are effective in lowering LDL-C levels [6][8]. - The introduction of new therapies, such as Novartis's siRNA drug inclisiran, which offers a more convenient dosing schedule, further enhances the options available for patients [8].